Hernia Mesh Lawsuit

Thousands of hernia mesh lawsuits are pending in courts across the country. Our hernia mesh lawyers are handling these cases in all 50 states.

The plaintiffs in these lawsuits are individuals with defective hernia mesh implanted during surgery, causing them to suffer severe post-surgical complications and injuries.

The hernia mesh lawsuits involve multiple hernia mesh products made by four medical device companies that are in (or were in) the litigation: Ethicon (a Johnson & Johnson subsidiary that has reached a settlement in most of its lawsuits), C.R. Bard (now part of Becton Dickinson), Covidien, and Atrium Medical Corp.

The alleged defects and product liability claims share enough in common to discuss together, but each litigation is at a different stage. We explain where they stand in 2026, including what has settled and which cases are still moving toward trial.

We also explain the latest Bard hernia mesh settlement news, our projected average settlement amounts, the $88 million Covidien verdict, and whether victims can still file a lawsuit.

For many, it is not too late to file your hernia mesh lawsuit, even after the Bard settlement. But you want to act now. Call our hernia mesh attorneys today at 800-553-8082.

Hernia Mesh Lawsuit Status in October 2026

In 2026, hernia mesh litigation is mature. Some defendants have settled large inventories. Some MDLs are winding down. But the litigation is not over. New cases are still being filed, and some parts of the litigation, especially the Covidien and Bard mesh cases, remain very active.

Federal action counts come from the October 1, 2026 JPML report. Medtronic’s broader plaintiff inventory comes from its quarterly SEC filing. These figures measure different things and should not be added together.

Average Hernia Mesh Lawsuit Settlement Amounts in 2026

One thing plaintiffs need to understand about the Bard settlement is that average payout numbers can be misleading.

A settlement average does not tell you what an individual case is worth. A plaintiff with chronic pain complaints but no revision surgery is in a very different position than someone with a documented bowel obstruction, infection, adhesions, recurrence, mesh migration, or organ perforation. The cases with the best value are usually the ones where the medical records tell a powerful story of pain and suffering.

What do we think the average hernia mesh settlement will be? Our guess, and we are getting closer to the end of this thing, is that the average hernia mesh payout will be between $65,000 and $70,000.

That remains our estimate, not a verified average of payments under the Bard settlement. The actual settlement agreement is confidential, and Bard has not published a definitive average payment per plaintiff.

We have always said that the potential settlement range in hernia mesh litigation is extremely broad. Based on earlier mesh verdicts and settlements, our lawyers have projected individual case values ranging from approximately $10,000 to $1 million, depending on the injuries and the strength of the evidence. That is a valuation opinion, not an announced settlement schedule.

The reason this range is so broad is that the value of each individual claim will vary significantly based on the level of injury involved.

Bard Settlement Payouts Are Different From Covidien Settlement Estimates

The Bard settlement was announced in October 2024. It covers a vast majority of the company’s existing hernia mesh litigation, including claims pending in the Ohio federal MDL and the Rhode Island state court proceeding. Payments are being administered over multiple years.

Covidien is in a very different position. There is no announced global settlement in the Covidien hernia mesh MDL. The $88 million verdict in August 2026 increased the company’s potential exposure, but it is being challenged and cannot be used to calculate an average Covidien settlement.

Generally, conventional wisdom holds that these are, on average, stronger cases than the Bard claims. We have also said that many lawyers expect Covidien settlement amounts to be higher than Bard’s. But that remains to be seen.

For now, the important distinction is that Bard is administering a major settlement, while Covidien is still litigating cases and preparing for additional jury trials.

What Makes a Hernia Mesh Case Worth More?

We are not just looking at the number of surgeries. The important question is what the surgeon found. If the operative report describes the mesh attached to the bowel, difficult removal, infection, shrinkage, or other physical evidence of a problem, the case is in a different category from one involving pain that cannot be connected to the implant.

Can You Still File a Hernia Mesh Lawsuit in 2026?

Yes. Hernia mesh lawsuits are still being filed in 2026. But this is not 2018 or 2019 anymore. The easy filing phase is over. Lawyers are more selective now because of obligations the court has imposed to show proof earlier in the claim. But there are still a lot of good cases out there.

Our firm is only taking revision cases. Why? Revision surgery gives the case a clearer injury story. A patient can say the mesh was implanted, serious complications followed, doctors had to go back in, and the mesh had to be removed or repaired. That sequence is just much stronger than a case involving discomfort alone, even though we fully understand how awful that is for many.

If you had hernia mesh implanted and later required revision surgery, the first step is getting the implant records. The product sticker, operative report, hospital records, and revision surgery records are critical. Without product identification, the case is very difficult.

Many of these cases are coming from patients who only recently connected their chronic pain or surgical complications to their earlier mesh implant. That delay between implantation and diagnosis is common and expected.

Hernia mesh complications often emerge slowly over time as the material breaks down, adheres to tissue, migrates, or causes infection or inflammation. A person might live for months or even years with unexplained pain, digestive issues, or hernia recurrence before a doctor pinpoints the underlying issue as mesh failure. So these cases will go on for a while.

But do not assume a recent diagnosis automatically gives you a new filing deadline. Statutes of limitations and statutes of repose vary by state. Some claims may already be time-barred, and waiting for another settlement announcement can make that problem worse.

Hernia Mesh Lawsuit Updates and News

These are the latest hernia mesh lawsuit updates. We are paying particular attention to the Covidien trials and the next stage of the Bard settlement.

Read Earlier Hernia Mesh Lawsuit Updates

August 20, 2026: Judge Saris Suggests Cutting the Verdict

Judge Saris is signaling that she is likely to reduce the recent $88 million Covidien hernia mesh verdict.

The judge says that she has begun reviewing comparable verdicts and the law governing remittitur, which gives a judge wide discretion to reduce what the court thinks is an excessive jury award.

The judge would rather the parties just agree to settle the case on their own, but that is a difficult chore because it is a guessing game of what one person thinks a fair verdict would be.

October 2026 clarification: These were the judge’s preliminary comments. Covidien filed post-trial challenges, and no final ruling reducing the award has been identified as of this update. See the current verdict discussion below.

August 18, 2026: Conference Tomorrow

Judge Saris has called Covidien mesh lawyers back before her tomorrow for a remote status conference.

The recent $88 million verdict is almost certain to come up, and you would think the judge will use the conference to push both sides on whether there is a realistic path toward resolving these cases. Covidien would be foolish not to jump at the opportunity.

August 5, 2026: The Huge Verdict We Have Been Waiting For

A Massachusetts federal jury awarded $88 million to a man injured by Covidien’s Symbotex hernia mesh in the first bellwether trial to reach a verdict in the litigation.

It was bad luck we did not get a blockbuster verdict in the Bard trials. This is a huge boon for the more than 2,400 Covidien hernia mesh cases pending in the federal litigation (and the remaining Bard cases, too).

We explain the jury’s findings and Covidien’s post-trial challenges in our current verdict analysis.

August 3, 2026: Covidien Bellwether Goes to Jury After Claims Company Hid Symbotex Risk

Closing arguments are complete in the first Covidien hernia mesh bellwether trial.

The plaintiff alleges that Covidien misled surgeons about how long Symbotex mesh’s collagen barrier would protect the bowel. His lawyers told jurors that Covidien’s internal evidence showed the barrier could dissolve within seven days, while sales representatives were instructed to tell doctors it lasted for as long as a month.

Covidien responded with the familiar defense playbook: blame the victim. It pushed studies supporting Symbotex, the plaintiff’s diabetes, obesity, and prior abdominal surgery, and argued that those factors caused the recurrence with or without the mesh.

Covidien also asked the judge to dismiss the warning claim because Patterson’s surgeon did not read the written instructions. That is a tough argument. The warning claim encompasses what company sales representatives told doctors, and that the label contained only generic references to adhesions, without disclosing that the protective barrier could disappear within a week. That argument will not fly.

The question is whether Covidien knew the feature intended to protect the bowel might disappear much sooner than surgeons were told and failed to give doctors information they needed to choose another product or surgical approach.

July 15, 2026: Plaintiffs Tell Jury Covidien Hid the Real Symbotex Risk

Plaintiffs gave the jury a straightforward explanation of what allegedly went wrong with Covidien’s Symbotex mesh. The device included a collagen barrier intended to keep the polyester mesh from attaching to the bowel while the patient healed. Plaintiffs contend that the barrier could dissolve far more quickly than doctors were told, leaving the bowel exposed to the mesh before healing was complete.

These are good facts for the plaintiff because the injury is supported by surgical evidence.

July 13, 2026: First Covidien Bellwether Trial Begins

The first Covidien hernia mesh bellwether trial is now underway in federal court in Massachusetts. The Patterson case is the first opportunity for plaintiffs to present the Symbotex defect and warning claims to an actual jury after years of motions, expert challenges, and discovery.

For plaintiffs, getting this case to trial has been a long journey. Covidien tried to defeat the claims before trial, but Judge Saris allowed the core failure-to-warn and several other claims to proceed. Now Covidien has to defend the product and its warnings in front of jurors instead of only through motions and expert reports.

May 4, 2026: New Mesh Cases

Our law firm is still taking new hernia mesh lawsuits after the settlement. The Covidien MDL has 2,396 pending federal actions as of May 1.

Unlike many law firms, ours is still reviewing claims from victims.

March 4, 2026: Covidien Case Count

Covidien is facing more than 2,200 hernia mesh lawsuits in the Massachusetts federal MDL before Judge Patti Saris. Many of the claims focus on mesh products such as Symbotex and Parietex, and plaintiffs say the materials can degrade, shrink, or trigger inflammatory reactions that lead to chronic pain, adhesions, infections, recurrence, and revision surgery.

Plaintiffs are finally getting what these MDLs often delay for years: a real jury trial. A bellwether does not bind the rest of the docket, of course, but it is the first time plaintiffs get to put the product, the corporate conduct, and the injury story in front of actual jurors. That matters because defendants can file motions and fight discovery forever, but a trial date forces a moment of truth.

September 1, 2025: More Lawsuits Filed Before Possible Settlement

An increasing number of Covidien hernia mesh lawsuits are being filed in anticipation of a possible settlement.

In a new lawsuit filed on Friday in the District of Massachusetts as part of the Covidien Hernia Mesh MDL, a New Mexico resident alleges that he suffered serious complications following the implantation of a defective hernia mesh product manufactured by Covidien LP and Sofradim Production SAS. The plaintiff claims he was implanted with the Parietex Optimized Composite Mesh on or about August 2, 2021, in New Mexico, and has since required corrective surgery due to complications from the device.

The lawsuit incorporates claims from the MDL’s Master Complaint, asserting causes of action for strict product liability (defective design, failure to warn, and manufacturing defect), negligence, gross negligence, and violations of both New Mexico and Massachusetts consumer protection laws. It also alleges breach of warranty, negligent and intentional infliction of emotional distress, fraudulent misrepresentation and concealment, and seeks punitive damages.

July 29, 2025: Strattice Hernia Mesh Lawsuits

The Strattice hernia mesh litigation is quietly evolving into a significant but often overlooked mass tort. While Bard and Covidien dominate the conversation, largely because of the enormous number of cases filed against them, Strattice has remained under the radar.

Strattice is made from porcine tissue and is a non-cross-linked acellular dermal matrix. It was marketed as an alternative to synthetic mesh for hernia repair, especially in complex or high-risk patients. Plaintiffs now argue that it causes many of the same problems as its synthetic counterparts, including chronic infections, foreign body responses, and tissue degradation.

While many Strattice cases were filed in New Jersey state court and coordinated through a multicounty litigation, a separate group has been litigated in federal court in the District of New Jersey.

This is not just a smaller version of Bard. It is a distinct battleground, and for plaintiffs’ lawyers already working in the mesh space, it offers another path forward. The Strattice litigation may shape how courts and juries view biologic mesh and open the door to broader scrutiny of devices once assumed safer simply because they were not synthetic.

July 10, 2025: Bard Mesh Lawsuits Moving Forward

Our lawyers are still seeing a steady flow of new Bard hernia mesh lawsuits. Not a ton of lawyers are looking at new cases but we are.

The process for settling new cases is still likely pretty far away. That is the reality. The next major procedural step will not begin until January 2027, when the court launches the Intensive Settlement Process (ISP).

Bard might decide it wants to get rid of these cases hanging over its head and offer a fair settlement. This is possible. But honestly, we think it is unlikely.

April 1, 2025: More Bard Lawsuits

The Bard litigation is settled, but many cases are still out there to be filed. In one new lawsuit filed last month, a Mississippi resident filed a product liability action in Newark, New Jersey, against C.R. Bard, Inc., alleging severe and permanent injuries resulting from the implantation of the company’s Ventralex hernia mesh devices. The plaintiff underwent two hernia repair surgeries in Oxford, Mississippi, in August 2020 and again in March 2022, during which Bard’s mesh devices were implanted and later removed due to complications.

The complaint alleges that the devices were defectively designed and manufactured, incorporating polypropylene materials alleged to degrade and provoke chronic inflammatory responses in the body. The plaintiff contends that C.R. Bard failed to adequately warn of the risks of mesh contraction, migration, and long-term complications, including organ adhesion, pain, and recurrent hernias. The suit further claims that Bard’s marketing misrepresented the safety and effectiveness of the device and concealed adverse outcomes despite access to pre- and post-market data highlighting the risks.

The plaintiff seeks compensatory and punitive damages under New Jersey’s Products Liability Act, asserting that safer alternative treatments existed. The case was initially filed in Bergen County Superior Court and removed to federal court.

March 6, 2025: More Time for Settlement

Individuals who have joined the group lawsuit against Bard over injuries caused by its allegedly defective hernia mesh implants will now have additional time to submit their claims. Due to ongoing technical issues with the Crosslink Portal, the designated platform for submitting medical records and supporting evidence, many claimants have experienced difficulties uploading their required documentation. These issues led to a delay in the original March 17, 2025 filing deadline, which was extended by several months to allow affected plaintiffs more time to complete their submissions.

Even with the extended deadline, act quickly. Delaying documentation can delay a settlement or jeopardize participation in a particular settlement program.

While the deadline extension provides some relief for those struggling with the portal issues, it does not change the fundamental reality that these settlements involve substantial administration. For claimants, the best course of action remains proactive engagement, working closely with attorneys to compile strong medical evidence and ensure their claims are submitted as quickly and comprehensively as possible.

February 20, 2025: Is the Covidien Settlement Getting Closer?

The Covidien litigation may be moving closer to potential settlement discussions as both sides have agreed to extend the deadline for selecting a mediator to February 24, 2025. The extension allows additional time for negotiations on choosing a neutral third party to oversee settlement talks, a key step to finally resolving these claims.

While the schedule for expert discovery remains largely unchanged, with plaintiffs’ expert reports now due by March 7, 2025, and defendants’ by April 18, 2025, the agreement to extend the settlement mediation deadline signals that both sides are looking to engage for the first time in real discussions that could lead to a resolution.

Though no settlement is guaranteed at this stage, the continued focus on mediation suggests that both parties are weighing potential resolutions while preparing for the bellwether trials. These early trials would play a significant role in determining liability and potential settlement values for the broader group of plaintiffs.

It is fair to say that many expect the Covidien settlement amounts to be higher than the ones we are seeing with Bard. But that remains to be seen.

Our lawyers are still taking new Bard and Covidien claims.

January 22, 2025: Bard Qualified Settlement Fund Approved

The MDL judge approved creating a Qualified Settlement Fund to manage settlement payments for individuals who experienced complications from Bard’s hernia mesh products.

This is a meaningful procedural step that moves the litigation closer to actual money reaching actual people. It does not mean that checks are imminent. We explain how the fund works in the current Bard settlement section.

December 1, 2024: Closer Look at CMO No. 55

CMO No. 55 establishes the Intensive Settlement Process (ISP) to facilitate the resolution of cases and appoints Ellen K. Reisman and John Jackson as Special Masters to oversee the process. Their duties include supervising settlement negotiations, mediating disputes, and ensuring that the ISP progresses efficiently. The Special Masters will report quarterly to the Court on the ISP’s status.

The ISP is scheduled to begin in January 2027. This is not a typo. Unresolved claimants who must go through the process can face an extraordinary wait before getting their cases back on an individual litigation track.

Monthly settlement conferences and mediations will then commence to address unresolved claims. Plaintiffs will be required to submit comprehensive settlement packages in advance.

The order includes a June 2029 provision for certain unselected substitute cases that have not had an opportunity to participate. It also provides a mechanism for some claimants to seek remand or trial earlier based on undue delay or unsuccessful settlement efforts. The precise rules matter, but the basic problem remains the same: many plaintiffs face a long wait.

November 13, 2024: Some Settlement Details

Some settlement details are out there, and I should have updated this space sooner…

There is a Quick Pay option. For straightforward cases, such as those involving a single surgery and less severe injuries, our earlier reporting described a fixed settlement amount of $25,000. For really weak cases that probably never should have been filed, some plaintiffs were offered $2,500. Claimants with more complex cases have the option to pursue higher-tier compensation, with payouts determined by the severity of their injuries.

As more claimants select the Quick Pay option, the lower-value claims are removed from the general pool, increasing the potential average payout for those with complex cases. This distribution allows for a larger share of the settlement funds to be allocated to claimants with the most significant injuries.

The downside? Payouts under these tiers may take between two to four years for final distribution.

Bard Hernia Mesh Settlement: What Happens Next?

The Bard hernia mesh litigation remains the largest hernia mesh MDL. Plaintiffs in the Bard cases allege that Bard and Davol sold polypropylene mesh products that caused chronic pain, infections, adhesions, recurrence, nerve damage, and revision surgery.

Bard announced a settlement in October 2024 to resolve the vast majority of its existing hernia mesh cases. The agreement includes federal cases in Ohio and claims in the Rhode Island consolidated litigation. The company did not disclose the total amount or a uniform average payment per plaintiff.

As the company’s announcement explains, payments are intended to be made over multiple years.

The Bard MDL is now in settlement mode, but you will see cases opt out of the settlement, and our lawyers are still getting calls with new cases. The MDL is still open, many cases remain pending on the docket, and the settlement process is still working through documentation, claim review, lien issues, and payment administration. You are also seeing a robust state court docket in Rhode Island where many cases have been filed regardless of where the plaintiff is from.

When Will Bard Hernia Mesh Settlement Checks Be Sent?

Some Bard claimants have already received settlement offers and payments. Others are still waiting for claim evaluation, documentation, lien resolution, or the next stage of the settlement process.

There is no single announced payment date that applies to everyone. The settlement terms are confidential, and individual payments depend on which agreement applies, whether the claim is eligible, the injury category, documentation, releases, and any outstanding liens.

Our lawyers have been saying for years that these settlements can move painfully slowly. Establishing a fund and reaching a global agreement are important steps. But those steps do not automatically put money in the hands of victims.

What Is the Bard Intensive Settlement Process?

Under Case Management Order No. 55, the court established an Intensive Settlement Process, or ISP, to address certain unresolved claims.

The court appointed Special Masters to oversee settlement efforts. The process is scheduled to begin on or about January 4, 2027.

Monthly conferences will address opt-out claimants, certain substitute cases, and other claims that have not been resolved through the settlement process. A claimant’s lawyer must submit a settlement package in advance, including the product identification, implant and revision records, evidence of injury, medical expenses, lien information, and settlement demand.

If the case does not settle at the conference, the parties generally proceed to mediation. The court order also establishes procedures governing payment when a case resolves through this process.

The frustrating part is the delay. The process may take years to work through all the claims. For some unselected substitute cases that have not had an opportunity to participate by June 1, 2029, the order permits an election to leave the ISP and pursue litigation under the applicable docket control order.

That June 2029 provision does not apply automatically to every unresolved Bard case. There are also provisions allowing some claimants who have completed the necessary court requirements to seek relief earlier if the settlement process has caused undue delay.

It is still a very long road for plaintiffs who want to try their cases. That has been our criticism of this settlement process from the beginning.

How Does the Bard Qualified Settlement Fund Work?

The MDL judge approved creating a Qualified Settlement Fund (QSF) to manage settlement payments for individuals who experienced complications from Bard’s hernia mesh products. This is a meaningful procedural step that moves the litigation closer to actual money reaching actual people.

A Qualified Settlement Fund is a court-supervised account specifically established to hold and distribute settlement proceeds. Rather than defendants writing checks directly to victims, the money first goes into the QSF, where it is held and managed by appointed administrators who oversee the distribution process.

This may not be how you expected it would go, but this structure serves several purposes. It allows defendants to take a tax deduction when the money is deposited into the fund, rather than waiting until individual payments are made. This extra time slows down settlement, but plaintiffs often need that time anyway to finalize allocation among claimants without rushing the distribution. And it provides a layer of court oversight that protects against disputes over how the money gets divided.

In a litigation of this size, with thousands of claimants asserting varying degrees of injury, the QSF structure is essential. Not every hernia mesh case involves the same product, the same complication, or the same severity of harm. Some plaintiffs required revision surgery or full mesh removal. Others suffered chronic infections, bowel obstruction, or permanent nerve damage. The fund administrators will follow a claims process to evaluate each case and determine the appropriate allocation based on injury severity, medical documentation, and other agreed-upon criteria. So the settlement has to account for all of that.

The establishment of the QSF, unfortunately, does not mean that checks are imminent. This will take a while. The good news is the infrastructure for resolution is being built. For plaintiffs who have been waiting years for this litigation to move toward closure, it is an encouraging sign.

What About Bard Quick Pay Settlement Options?

Our earlier reporting described a Quick Pay option for certain less complicated claims, including amounts of $25,000 for some cases and $2,500 for some particularly weak claims.

These are not universal settlement amounts available to every Bard plaintiff. The confidential settlement arrangements govern who can participate, what documentation is required, and how cases are classified.

Claimants with more serious complications may be eligible for a different valuation process. The downside is that higher-value claims can take longer to evaluate and resolve.

Before accepting any offer, plaintiffs should understand whether they would be releasing all claims, what liens or expenses will be deducted, and how much they are expected to receive after the required deductions.

Can You File a New Bard Hernia Mesh Lawsuit After the Settlement?

Yes, potentially. The 2024 agreement did not create a universal legal bar against future claims. The question is whether the person has a viable claim, can identify the Bard product, has sufficient evidence of injury, and can still sue under the applicable law.

Not every new claimant will qualify for the existing settlement program. New cases may have to proceed through separate litigation or settlement arrangements.

Our lawyers are still reviewing new Bard hernia mesh claims involving revision surgery. We are more selective now, and the records have to support the case.

For more specific Bard settlement reporting, see our Bard hernia mesh lawsuit updates.

Covidien Hernia Mesh Lawsuit: The $88 Million Verdict and What Comes Next

The Covidien hernia mesh litigation is the most active hernia mesh battlefield in 2026. These lawsuits involve products made by Covidien and related entities, including mesh products such as Parietex and Symbotex.

Plaintiffs allege that certain Covidien mesh products can degrade, shrink, trigger inflammatory reactions, adhere to tissue, cause chronic pain, and require corrective surgery. The allegations are familiar, but the products and proof are different from Bard, Ethicon, and Atrium.

Covidien Faces Approximately 10,500 Hernia Mesh Plaintiffs

The number of Covidien lawsuits is much larger than the federal MDL count would lead you to believe.

In an August 2026 SEC filing, Medtronic reported that the company and its subsidiaries were defendants in hernia mesh litigation brought on behalf of approximately 10,500 individual plaintiffs.

Approximately 7,450 plaintiffs had pending claims in a coordinated Massachusetts state court proceeding. Another 500 were in Minnesota state court, approximately 2,400 federal actions were pending in the Massachusetts MDL at the time of the filing, and roughly 150 claims were outside the United States. Fewer than ten individual cases were also pending elsewhere.

The October 1 JPML report subsequently counted 2,479 federal Covidien actions. That is the federal MDL number, not the entire inventory.

Why does this matter? Settlement negotiations are driven in part by the size of the company’s exposure. Covidien is defending claims involving thousands more people than the federal MDL number suggests. And these cases involve different products, injury patterns, and legal theories.

Covidien has not resolved the litigation the way Bard has. Bellwether trials are now creating real settlement pressure. If plaintiffs score additional meaningful trial wins, the value of the Covidien cases could rise quickly.

The Patterson $88 Million Hernia Mesh Verdict

On August 4, 2026, a Massachusetts federal jury awarded $88 million to Larry Patterson and his wife in the first Covidien hernia mesh bellwether trial to reach a verdict.

The award included $77 million for Patterson and $11 million for his wife’s loss-of-consortium claim.

The jury found that Covidien failed to adequately warn doctors about how quickly Symbotex mesh’s protective collagen barrier could dissolve. Plaintiffs presented evidence that the barrier largely disappeared within one week, even though doctors were allegedly led to believe it could provide protection for as long as a month.

Patterson later suffered a bowel obstruction after the mesh allegedly adhered to his bowel. During corrective surgery, doctors found the mesh attached to his small bowel, requiring a bowel resection.

These are good facts for the plaintiff because the injury is supported by surgical evidence.

Covidien defended the case by pointing to the patient’s diabetes, obesity, prior abdominal surgery, and the known risks of hernia repair. The company argued that those factors caused the recurrence and complications rather than a problem with its warnings or mesh.

But the warning evidence was the heart of the case. Plaintiffs contended that Covidien’s sales representatives described protection from the collagen barrier that lasted longer than the company’s own testing supported.

The jury rejected the fraud claim and did not award punitive damages. The plaintiffs had also dropped their design-defect and warranty claims during trial, so the verdict rested on the failure-to-warn theory.

Will the Judge Reduce the $88 Million Verdict?

That is an important unresolved question.

Judge Patti Saris discussed the possibility of reducing the award after the verdict. Covidien subsequently filed post-trial motions challenging the result and requesting relief that includes a new trial or reduction of the damages award.

As of this October 2026 update, no final ruling reducing the verdict has been reported. The $88 million remains an important jury result, but it is not a final, unchangeable judgment that can be used to calculate everyone else’s settlement.

This puts the plaintiff in an untenable position if the court ultimately reduces the award. The plaintiff could reject a lower amount and face another trial. But any reduction may still leave a life-changing amount of money, and there is never a guarantee of winning again.

For the broader litigation, the verdict still matters enormously. Covidien now has to consider the possibility that future juries will respond similarly to evidence of what the company knew and what doctors were told.

The Next Covidien Bellwether Trials

These two trials could tell us a lot more about the settlement value of Covidien cases.

The second case tests whether another jury agrees with the allegations involving Symbotex’s protective coating. The third examines a different mesh design and a different injury pattern.

Covidien can continue fighting each case individually. But the larger the range of products and injuries that produce substantial plaintiff verdicts, the harder it becomes for the company to argue that Patterson was just an outlier.

What Really Matters for Covidien Plaintiffs?

The June 2, 2026 summary judgment order shows why the first bellwether reached trial. Judge Saris denied summary judgment on numerous claims, including failure to warn, while reserving a ruling on design-defect theories. The jury later returned its verdict on the warning claim.

Hernia Mesh Manufacturers and Products Named in Lawsuits

There is not one hernia mesh lawsuit. Several different litigations against different manufacturers involve different mesh products. The federal cases have been handled in separate multidistrict litigations, known as MDLs.

An MDL is not a class action. In a class action, one or a few plaintiffs usually represent the entire class. In an MDL, each plaintiff keeps an individual lawsuit, but the cases are coordinated before one federal judge for discovery, expert challenges, bellwether trials, settlement efforts, etc.

Our firm’s current intake remains focused on qualifying Bard and Covidien cases involving revision surgery. We also report on Atrium, Ethicon, Strattice, ProLite, and ProLoop litigation because readers need to understand what happened with these other products. That reporting does not mean we are accepting new claims involving every product listed below.

Bard Hernia Mesh Products

Bard products named in lawsuits have included devices such as:

• Ventralex
• Ventralex ST
• PerFix Plug
• 3DMax
• 3DMax Light
• Composix
• Composix Kugel
• Ventralight ST

Whether a specific product was involved in litigation does not establish that every implant of that product was defective. The identification, injury, medical evidence, and legal claims still matter.

Covidien Hernia Mesh Products

Covidien lawsuits have involved products such as Symbotex, Parietex Composite, Parietex Optimized Composite, and Parietex ProGrip.

One of the biggest differences among these claims is the specific defect alleged. Symbotex plaintiffs have challenged the performance and warnings associated with its collagen barrier. ProGrip claims involve a different mesh construction and can raise issues concerning pain, tissue integration, and injury to nearby structures.

That distinction is important. Plaintiffs should not assume the Patterson verdict establishes the value or liability of every Covidien mesh claim.

Atrium C-Qur Hernia Mesh Lawsuits Are Winding Down

The Atrium C-Qur MDL is also much smaller than it used to be. The lawsuits alleged that Atrium C-Qur mesh products were defectively designed and that the coating and mesh materials could cause inflammation, adhesions, infection, pain, recurrence, and revision surgery.

Atrium C-Qur cases were once one of the main hernia mesh litigation tracks. In 2026, however, the MDL is winding down. The number of pending federal cases has dropped significantly, and the litigation no longer has the same energy it had during its peak.

That said, the allegations in Atrium cases still matter because they illustrate the broader problem with permanent mesh implants. Plaintiffs contend that manufacturers sold products that could interact badly with tissue, trigger an inflammatory response, and create complications that were not adequately disclosed to doctors and patients.

Ethicon Physiomesh Lawsuits

Ethicon, a Johnson & Johnson subsidiary, faced thousands of lawsuits involving Physiomesh Flexible Composite Mesh. Plaintiffs alleged that the product could cause hernia recurrence, chronic pain, adhesions, and other complications requiring revision surgery.

Ethicon withdrew Physiomesh Flexible Composite Mesh from the global market in 2016, and the federal MDL later resolved most of its claims through settlements and dismissals.

In 2026, the federal Physiomesh MDL is effectively resolved. It is not the same active litigation opportunity as Covidien or the remaining Bard cases.

ProLite and ProLoop Hernia Mesh Lawsuits

The ProLite and ProLoop lawsuits are a separate story. ProLite and ProLoop are polypropylene hernia mesh products associated with Atrium Medical Corp. Plaintiffs have alleged that these products can cause chronic inflammation, infection, adhesions, pain, degradation, and the need for revision surgery.

Lawyers for some plaintiffs asked the Judicial Panel on Multidistrict Litigation to create a new MDL for ProLite and ProLoop cases. The JPML denied that request. So these cases did not become a large consolidated federal MDL like Bard, Ethicon, Atrium C-Qur, or Covidien.

That changes the litigation strategy. Without an MDL, ProLite and ProLoop cases proceed as individual lawsuits or through informal coordination among lawyers. That can be good and bad for plaintiffs. The good news is that an individual case may move faster than it would in a massive MDL. The bad news is that plaintiffs do not get the same shared discovery machine, coordinated expert work, and bellwether structure that can help build settlement pressure.

Our firm is currently focusing its hernia mesh intake on Bard and Covidien revision cases. We include ProLite and ProLoop here to explain the litigation, not as an announcement that we are accepting new claims involving those products.

Strattice Hernia Mesh Lawsuits

Strattice is a different kind of hernia repair material. It is a biologic mesh made from porcine tissue, specifically a non-cross-linked acellular dermal matrix.

Plaintiffs have alleged that Strattice can cause complications involving infection, tissue response, degradation, and revision surgery. These cases raise different scientific questions from lawsuits involving polypropylene or polyester mesh.

Strattice deserves attention in its own right because the litigation challenges the assumption that biologic mesh is necessarily safer simply because it is not synthetic.

But the medical literature also contains evidence supporting the use of non-cross-linked biologic matrices in selected complex repairs. The case still has to be proven through the particular product, surgical circumstances, complication, and medical evidence.

As with ProLite and ProLoop, our discussion of Strattice does not mean the product is part of our current Bard and Covidien intake.

What Are the Hernia Mesh Lawsuits About?

A hernia mesh is a small piece of surgical mesh used to reinforce weakened tissue after a hernia repair. The basic idea is simple. The surgeon repairs the hernia, places the mesh over or under the weakened area, and the mesh is supposed to help strengthen the repair so the hernia does not return.

When the product works, it is great. When it fails, what you thought was a routine hernia repair becomes years of pain, infections, adhesions, bowel problems, nerve injury, and repeat surgeries.

We allege that certain hernia mesh products were defectively designed, defectively manufactured, or sold without adequate warnings. Many of the claims focus on polypropylene mesh, coatings, barrier layers, plugs, patches, and composite designs that allegedly failed to behave safely once implanted in the human body.

Our lawsuits allege that certain hernia mesh products were not safe for permanent implantation. Some products triggered chronic inflammation because their materials were not biologically inert. In other words, the body did not quietly accept the mesh. Instead, the immune system allegedly reacted as if it were a foreign object.

Other mesh products allegedly had design problems that caused the mesh to shrink, wrinkle, fold, migrate, erode into tissue, or attach to nearby organs. In some cases, plaintiffs allege the mesh became embedded in tissue so aggressively that removing it required complicated revision surgery.

These alleged failures can cause serious complications, including:

• Chronic abdominal or groin pain
• Infection
• Inflammation
• Adhesions
• Bowel obstruction
• Mesh migration
• Mesh shrinkage or contraction
• Organ perforation
• Nerve injury
• Hernia recurrence
• Need for revision surgery

The FDA’s hernia mesh information discusses complications involving pain, infection, recurrence, adhesions, obstruction, migration, and shrinkage. Some complications can also happen after hernia repair without mesh. A lawsuit therefore requires more than showing that a complication occurred after surgery.

The question for the individual case is whether the product was defective or inadequately labeled and whether that problem caused the patient’s injury.

What Can Revision Surgery Records Show?

The revision surgery operative report may document adhesions, a bowel obstruction, recurrence, migration, shrinkage, infection, or difficult removal. Pathology reports and photographs can be useful, too.

There is no guarantee that revision surgery means the mesh was defective. But from a trial lawyer’s perspective, the evidence is often much stronger when the surgeon actually observed and documented the condition of the implanted device.

How Do You Find Out Which Hernia Mesh Was Implanted?

The first place to look is the operative report from the original hernia repair. Hospitals frequently keep implant logs, product stickers, and records identifying the manufacturer and model.

Patients may also have an implant card or other documentation. If the mesh was removed, the revision surgery records may identify the original product and describe what happened to it.

The FDA also recommends obtaining the manufacturer, brand name, and unique device identifier after hernia mesh surgery. Those records may help determine whether the product has been associated with particular safety information or litigation.

What Is the Nutshell of the Allegations in the Bard Hernia Mesh Lawsuits?

If you are trying to understand the Bard hernia mesh lawsuits, the core allegation is pretty straightforward. Plaintiffs say Bard sold hernia mesh products that were supposed to help repair their bodies, but instead caused serious and sometimes life-changing complications. Bard, a subsidiary of Becton Dickinson, manufactured the hernia mesh devices at the center of these claims.

We argue that these products were defectively designed and improperly manufactured. We also say that the mesh did not perform the way a safe medical device should. Instead of acting like a sturdy patch on a torn sail, plaintiffs claim the mesh sometimes became the very thing that created more damage. The alleged complications include chronic pain, infections, mesh migration, mesh shrinkage, organ perforation, and hernia recurrence. For many patients, that meant more surgery, more pain, and a longer road than they ever expected.

Allegation That Bard Knew of the Risk

A major allegation in the Bard hernia mesh litigation is that Bard knew or should have known about the risks associated with its mesh products and failed to give doctors and patients fair warnings. This allegation really drives these cases. A complication is one thing. But what if the manufacturer understood the danger and still did not clearly tell the people who needed that information most?

So our lawyers contend that Bard did not adequately disclose the risk of serious mesh-related complications or provide proper instructions for safe use of the devices. The argument is that surgeons and patients were left without a full picture of the risks before these products were implanted.

Compensation Sought

The plaintiffs are seeking compensation for the harm they say Bard’s hernia mesh products caused. That includes damages for physical injuries, chronic pain, additional surgeries, emotional distress, medical bills, lost wages, and the cost of future care.

These lawsuits are not just about the mesh failing. They reflect the human cost when a medical device allegedly creates more problems than it solves. If you had a hernia repair and later needed revision surgery, suffered ongoing pain, or developed serious complications, you can see why plaintiffs are pushing to hold Bard accountable. The claim is that patients trusted the product to help fix one problem, but for too many people, it allegedly opened the door to another.

Settlements in Prior Hernia Mesh Cases

Estimating the potential settlement amounts of product liability claims in a mass tort is hardly an exact science. Too many variables and unknowns can drastically affect settlement compensation.

We do have some prior verdicts and settlements involving hernia mesh. These results give us some basis to come up with a reasonable value estimate for the present cases.

The Earlier Composix Kugel Hernia Mesh Settlement

In 2011, Bard negotiated approximately $184 million to resolve about 2,600 Composix Kugel hernia mesh claims. These were older cases involving a different product and litigation from the Bard MDL that began in 2018.

The Composix Kugel claims involved allegations of complications including bowel perforation, infection, fistulas, and other serious injuries associated with the hernia patch.

The $184 million agreement works out mathematically to approximately $70,800 per claim. But that does not mean each plaintiff received that amount. Settlement distributions depend on the injury, the evidence, the applicable agreement, and other factors. The amount also covered settlement and administration costs.

Bard disclosed the settlement in a June 30, 2011 SEC filing. The plaintiffs’ lawyers also reported the approximately 2,600-case resolution.

The Kugel settlement is a useful historical comparison. It does not establish the average payout in the later Bard settlement or predict what a Covidien claim will be worth.

Verdicts in the More Recent Bard MDL

The newer Bard polypropylene hernia mesh MDL produced mixed trial results before the 2024 settlement.

• September 2021: The first federal Bard bellwether trial ended in a defense verdict.
• April 2022: The second federal Bard bellwether produced a $255,000 plaintiff verdict.
• August 2022: A Rhode Island state court jury returned a verdict exceeding $4.8 million against Bard.
• November 2023: The third federal Bard bellwether ended in a $500,000 plaintiff verdict.

These were not Kugel bellwether trials. They involved the more recent Bard litigation and different mesh products and allegations.

The $88 Million Covidien Verdict

And then came Patterson, with an $88 million Covidien verdict in August 2026. A gamechanger.

But the range of results shows that different juries have different takes on these cases and it also show how case specific these case are.  Each one has its own unique facts that have led to different verdicts.   They also show why it would be a mistake to assume that the largest jury verdict represents the likely settlement value of an ordinary case because it certainly does not.

If you think your case is more serious than the average and deserves a higher settlement, you may choose to opt out of the settlement program and keep going forward with your claim when the agreement and court orders permit it. But doing so carries risks, including litigation costs, delays, and the possibility of losing entirely.  So should you? It really depends on the facts of the case.

For more detail on our approach to case valuation, see our hernia mesh settlement value discussion.

Hernia Mesh Lawsuit Frequently Asked Questions

What is the average settlement for a hernia mesh lawsuit?

Our lawyers estimate that an average hernia mesh settlement may fall in the $65,000 to $70,000 range for the Bard litigation for cases with a meaningful injury.  We have less of a feel for Covidien, but we think the Covidien cases are even stronger and the settlement amounts will be higher.  That is just our opinion based on the evidence against the defendant (and that $88 million verdict does not hurt this theory).

Are Bard hernia mesh settlement checks being sent out in 2026?

Bard settlement payments are being administered over multiple years. There is no single payment date for all claimants. Eligibility, documentation, injury category, releases, medical liens, and the terms of the applicable settlement arrangement affect when an individual receives their settlement check.

When will the Covidien hernia mesh lawsuits settle?

There is no announced global Covidien hernia mesh settlement. The August 2026 $88 million verdict may increase settlement pressure, but it remains subject to post-trial challenges. Additional trials are scheduled for January 11 and March 29, 2027. Those results could affect negotiations.

How many Covidien hernia mesh lawsuits have been filed?

The October 1, 2026 JPML report listed 2,479 pending federal Covidien actions. But Medtronic disclosed approximately 10,500 individual plaintiffs across its broader hernia mesh litigation as of August 5, 2026. That larger inventory includes federal cases and claims pending in state courts, particularly Massachusetts and Minnesota.

Can I still file a hernia mesh lawsuit after the Bard settlement?

Potentially. The Bard settlement did not bar every future claim. A new claimant still needs to establish the product, injury, causation, and a timely claim. Not every newly filed lawsuit will be eligible for the existing settlement program. Our firm is still reviewing cases involving revision surgery.

Do I need revision surgery to qualify for a hernia mesh lawsuit?

Our firm’s current screening criteria require revision surgery involving the mesh. That is our law firm’s intake policy, not a condition you must meet before filing a lawsuit, and there are certainly serious cases without a revision.   Our lawyers are looking for cases where the medical records document a serious complication and what surgeons found when they went back in.

What hernia mesh products are involved in lawsuits?

Litigation has involved Bard products such as Ventralex, Ventralight ST, PerFix Plug, 3DMax, and Composix; Covidien products including Symbotex and Parietex; Atrium C-Qur; and Ethicon Physiomesh. Most people calling us have no idea which specific manufacturer was used, much less the model.  We figure out the specific product and manufacturer through the medical records.

Is your firm accepting Strattice, ProLite, or ProLoop lawsuits?

Our current advertised intake focuses on qualifying Bard and Covidien hernia mesh cases involving revision surgery. We discuss Strattice, ProLite, and ProLoop for readers following those litigations, but we are not accepting new claims involving those products under our current screening criteria.

Is there a hernia mesh class action lawsuit?

The major remaining major federal hernia mesh product liability lawsuits (Bard and Covidien) are organized into separate multidistrict litigations, or MDLs, by manufacturer. An MDL is different from a class action because, unlike a class action lawsuit, each plaintiff retains an individual lawsuit. The cases are coordinated for discovery, motions, and other pretrial proceedings.

What records should I get before calling a hernia mesh lawyer?

Start with the original operative report, implant record or product sticker, and records from the revision surgery. Imaging reports, pathology, hospitalizations, infection treatment, and information about future care may also be important. You do not have to assemble every record before contacting a lawyer.

Contact Us About Your Hernia Mesh Case

It is not too late for everyone to file a hernia mesh lawsuit. If you were injured by a hernia mesh implant and required revision surgery, our lawyers can investigate whether you have a viable claim.

We are still reviewing Bard and Covidien cases, even though some other firms have stopped taking new claims.

Call our hernia mesh lawyers today at 800-553-8082 for a free consultation.